CBD and Lennox-Gastaut Syndrome
FDA-approved CBD reduces drop seizures in severe childhood epilepsy when added to existing treatment.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Pharmaceutical CBD has real, measured seizure benefit in LGS—not a cure, but meaningful as an add-on. The FDA approval and randomized trials are genuine. However, this does not mean over-the-counter hemp CBD works the same way, and it absolutely requires neurologist oversight. It's evidence-based medicine, not a wellness product.
Not Medical Advice
This article is not medical advice. Lennox-Gastaut syndrome is a severe, treatment-resistant childhood epilepsy requiring specialist care. Any change to antiseizure therapy—adding CBD, adjusting clobazam, stopping valproate—must be made with a pediatric neurologist or epileptologist. Over-the-counter hemp CBD products are not equivalent to the prescription medication studied in the trials described here. Do not start, stop, or adjust any antiseizure drug without medical supervision.
Plain-Language Summary
Lennox-Gastaut syndrome (LGS) is a rare, severe epilepsy typically beginning between ages 3 and 5. It causes multiple seizure types, especially drop attacks (sudden loss of muscle control causing falls), along with cognitive impairment and a characteristic EEG pattern (slow spike-and-wave). Most children with LGS have seizures that continue despite multiple antiseizure medications.
Cannabidiol (CBD)—the non-intoxicating cannabinoid from cannabis—has been formulated as a prescription medication called Epidiolex. In two large, rigorous randomized controlled trials, it reduced drop seizures by 17–22 percentage points more than placebo when added to existing treatment [1][2] Strong evidence. The FDA approved it for LGS in June 2018.
This is not a cure and does not work for every child. Most patients still have seizures. However, it is a real, measurable benefit backed by Phase III evidence—which is more robust than almost any other cannabis claim in medicine.
What Probably Works (Strong Evidence)
Reduction in drop seizures. Two pivotal Phase III randomized, double-blind, placebo-controlled trials tested add-on CBD in children and adults with LGS.
In Devinsky et al. (NEJM, 2018), CBD 20 mg/kg/day reduced drop-seizure frequency by a median of 41.9% compared to 17.2% on placebo [1] Strong evidence. Thiele et al. (Lancet, 2018) reported a 43.9% median reduction with CBD versus 21.8% with placebo [2] Strong evidence.
Reduction in all-seizure frequency. Both trials showed statistically significant reductions in total seizure count as a secondary endpoint [1][2] Strong evidence.
Sustained benefit in open-label follow-up. Patients followed for up to ~2 years in open-label extension phases generally maintained their seizure reduction. Some developed tolerance, but discontinuation was not routine [4] Strong evidence.
Dose-response relationship. Comparative dosing trials found both 10 mg/kg/day and 20 mg/kg/day effective, with the lower dose often offering better tolerability [2] Strong evidence. Dosing is individualized rather than automatically escalated to the highest level.
What Might Work (Weak or Mixed Evidence)
Quality of life and caregiver burden. Secondary analyses of the pivotal trials suggest improvements in parental-reported outcomes and overall functioning, but these endpoints are subjective and were not primary trial goals Weak / limited.
Improved alertness and cognition. Some open-label reports describe improved daytime alertness and behavioral flexibility, but controlled data are limited. Confounders include concurrent reductions in other sedating antiseizure drugs and the complex pharmacodynamic interaction between CBD and clobazam Weak / limited.
Seizure freedom. Achieved in only a small proportion of patients. LGS remains a condition where the goal is typically seizure reduction, not elimination Weak / limited.
Over-the-counter CBD products (artisanal, hemp-derived). Case series and parent surveys exist, but these products vary widely in cannabinoid content and purity. Labeling inaccuracies are common [5] Weak / limited. Causality cannot be cleanly attributed to CBD when formulations are unverified.
What Doesn't Work or Lacks Evidence
Smoked or vaporized cannabis flower for LGS. No controlled evidence exists. THC exposure in children carries cognitive risks and is not appropriate for this indication No data.
'Full-spectrum is always superior to isolate.' This is marketing rhetoric, not clinical fact. The drug with the strongest evidence in LGS—Epidiolex—is highly purified CBD, not a full-spectrum product. While the 'entourage effect' is plausible in some contexts, it is not established for LGS Disputed.
CBD as monotherapy for LGS. All pivotal trials studied CBD as add-on therapy to existing antiseizure medications. There is no high-quality evidence supporting CBD alone No data.
Specific terpene profiles enhancing efficacy. No clinical data in LGS or comparable pediatric epilepsies No data.
What We Don't Know
- Long-term safety (10+ years) in children, including effects on liver health, neurodevelopment, and fertility.
- Mechanistic attribution. Whether seizure benefit reflects CBD itself, or partly an obligatory interaction with clobazam (CBD inhibits CYP2C19, raising N-desmethylclobazam levels) [6] Strong evidence. Sub-analyses suggest benefit in patients not on clobazam, but the effect size may be smaller Weak / limited.
- Predictors of response. No validated biomarkers, genetic tests, or clinical features reliably predict who will respond.
- Optimal dosing in adults vs. children beyond the narrow ranges tested.
- Equivalence of pharmaceutical vs. well-manufactured artisanal CBD at verified equivalent doses. This question is understudied because research trials use pharmaceutical-grade product.
- Whether CBD reduces underlying seizure burden or simply dampens acute seizure manifestation (a mechanistic distinction with unclear clinical relevance).
Comparison With Standard LGS Treatments
LGS is managed with combinations of antiseizure medications; no single drug reliably controls seizures. Standard agents include valproate, lamotrigine, rufinamide, topiramate, clobazam, felbamate, and the ketogenic diet. Non-pharmacological options include vagus nerve stimulation and corpus callosotomy [7] Strong evidence.
Head-to-head trials comparing CBD with other agents do not exist. Indirect comparisons across published add-on trials suggest CBD's effect on drop seizures is roughly comparable in magnitude to rufinamide and clobazam, and possibly greater than felbamate or lamotrigine [7] Weak / limited. These indirect comparisons are not definitive and should not guide clinical choice without specialist input.
CBD is typically added when two or more prior medications have failed and is layered on top rather than replacing existing therapy. Like other newer antiseizure medications, it is reserved for treatment-resistant cases.
Risks and Side Effects
Common adverse events reported in ≥10% of patients on CBD, exceeding placebo rates: somnolence, decreased appetite, diarrhea, fatigue, and elevated liver transaminases (ALT/AST) [1][2] Strong evidence.
Liver enzyme elevations are dose-dependent and significantly more frequent in patients also taking valproate. Monitoring of liver function tests is recommended, particularly in the first 6 months and when adding or changing concurrent medications [3] Strong evidence.
Clobazam interaction. CBD inhibits CYP2C19, raising levels of clobazam's active metabolite, N-desmethylclobazam. This increases sedation risk and may partly explain seizure reduction in patients on both drugs. Clobazam dose reduction is frequently required [6] Strong evidence.
Other drug interactions. CBD affects multiple cytochrome P450 enzymes (3A4, 2C9, 2C19) and is metabolized by them. Interactions with warfarin, certain antidepressants, and other antiseizure medications are possible [3] Strong evidence. See Cannabis and Polypharmacy Risks for broader context.
Suicidal ideation. FDA class warning for antiseizure medications; monitor closely in all patients, especially adolescents.
Abrupt withdrawal. CBD should not be stopped suddenly. Like other antiseizure drugs, it must be tapered to avoid rebound seizures.
Bottom Line
Pharmaceutical CBD (Epidiolex) is a legitimate, evidence-based add-on therapy for Lennox-Gastaut syndrome. It reduces drop-seizure frequency by a clinically meaningful margin on top of existing antiseizure medication. It is not a cure, not a wellness product, and not interchangeable with over-the-counter hemp CBD.
Decisions about starting, dosing, monitoring, or combining CBD with other antiseizure drugs belong with a pediatric neurologist or epileptologist who can track liver function, drug–drug interactions, and individual response. The benefit is real but requires specialist oversight and realistic expectations.
Sources
- Peer-reviewed Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal of Medicine. 2018;378(20):1888–1897.
- Peer-reviewed Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10125):1085–1096.
- Government U.S. Food and Drug Administration. Epidiolex (cannabidiol) Prescribing Information. FDA Drug Database.
- Peer-reviewed Thiele EA, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–428.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
- Peer-reviewed Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Frontiers in Neurology. 2017;8:505.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Withdrawal Syndrome — Real but not life-threatening withdrawal after heavy regular cannabis use.
- CBD and Dravet Syndrome — FDA-approved pharmaceutical CBD cuts convulsive seizure frequency by roughly half in Drave...
- Mamba Negra CBD — A CBD-marketed strain with no independent documentation or verifiable breeder record.
- Risks of Cannabis Use in Adolescents — Evidence summary of cannabis-related harms during critical brain development years.